Reviewer’s report

Title: Trastuzumab with either docetaxel or vinorelbine as first-line treatment for patients with HER2-positive advanced breast cancer: a retrospective comparison

Version: 3 Date: 22 December 2009

Reviewer: Hung Khong

Reviewer’s report:

Title: Trastuzumab with either docetaxel or vinorelbine as first-line treatment for patients with Her-2-positive advanced breast cancer: a retrospective comparison
Stefania Redana, et al.

OK for publication with the following minor comments:

1) In abstract, all letters after the semi-colon (;) should be capitalized. For example, Background: combinations… should be Background: Combinations…

2) In abstract, under Results, “docetaxel-trastuzumab resulted superior to vinorelbine-trastuzumab interms of response rate…and median overall survival.“ contains grammatical error. Suggestion: “Docetaxel-trastuzumab resulted in superior response rate…and median overall survival…compared with vinorelbine-trastuzumab.“

3) Page 12, last paragraph, third line, “…breast cancer is worth of…” should be “…breast cancer is worthy of…”

Level of interest: An article whose findings are important to those with closely related research interests

Quality of written English: Needs some language corrections before being published

Statistical review: No, the manuscript does not need to be seen by a statistician.